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Abstract
P-selectin glycoprotein ligand-1 (PSGL-1, CD162) is a cell-surface glycoprotein that is expressed,
either constitutively or inducibly, on all myeloid and lymphoid cell lineages. PSGL-1 is implicated in
cell–cell interactions between platelets, leukocytes and endothelial cells, and a key mediator of inﬂam-
matory cell recruitment and transmigration into tissues. Here, we have investigated the effects of the
β-1,4-galactosyltransferase inhibitor 5-(5-formylthien-2-yl) UDP-Gal (5-FT UDP-Gal, compound 1) and
two close derivatives on the cell surface levels of PSGL-1 on human peripheral blood mononuclear
cells (hPBMCs). PSGL-1 levels were studied both under basal conditions, and upon stimulation of
hPBMCs with interleukin-1β (IL-1β). Between 1 and 24 hours after IL-1β stimulation, we observed initial
PSGL-1 shedding, followed by an increase in PSGL-1 levels on the cell surface, with a maximal win-
dow between IL-1β-induced and basal levels after 72 h. All three inhibitors reduce PSGL-1 levels on
IL-1β-stimulated cells in a concentration-dependent manner, but show no such effect in resting cells.
Compound 1 also affects the cell surface levels of adhesion molecule CD11b in IL-1β-stimulated
hPBMCs, but not of glycoproteins CD14 and CCR2. This activity proﬁle may be linked to the inhibition
of global Sialyl Lewis presentation on hPBMCs by compound 1, which we have also observed.
Although this mechanistic explanation remains hypothetical at present, our results show, for the ﬁrst
time, that small molecules can discriminate between IL-1β-induced and basal levels of cell surface
PSGL-1. These ﬁndings open new avenues for intervention with PSGL-1 presentation on the cell sur-
face of primed hPBMCs and may have implications for anti-inﬂammatory drug development.
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Introduction
P-selectin glycoprotein ligand-1 (PSGL-1) is a cell-surface glycopro-
tein that is expressed, either constitutively or inducibly, on all mye-
loid and lymphoid cell lineages (Laszik et al. 1996). PSGL-1 binds
to P-, E- and L-selectin under ﬂow conditions, and is the main
physiological selectin ligand for leukocyte rolling on activated endo-
thelial cells (Carlow et al. 2009; Zarbock et al. 2011). In addition to
mediating leukocyte tethering and rolling, PSGL-1 also transduces
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signals into rolling leukocytes, and triggers platelet/leukocyte aggre-
gate formation and other forms of platelet/leukocyte interaction
(Carlow et al. 2009; Sreeramkumar et al. 2014). It has previously
been shown that platelets are essential for pulmonary leukocyte
recruitment, bronchial hyperresponsiveness and airway remodeling
in animals induced by both allergic and non-allergic stimuli
(Pitchford et al. 2003, 2004, 2005; Zarbock et al. 2006;
Tamagawa-Mineoka et al. 2007; Pitchford et al. 2008; Kornerup
et al. 2010). These events are driven by the cell surface levels of
PSGL-1 on leukocytes, and of P-selectin on the surface of activated
circulating platelets, as evidenced by the fact that administration of
either anti-PSGL-1 or anti-P-selectin antibodies almost entirely abro-
gates pulmonary recruitment of eosinophils, neutrophils and T cells
in mice (Pitchford et al. 2005, 2008; Kornerup et al. 2010). As a
critical step in the cascade of events required for the recruitment of
inﬂammatory cells, the P-selectin/PSGL-1 interaction therefore repre-
sents a promising target for therapeutic intervention, e.g., in chronic
inﬂammatory conditions such as asthma and COPD (Binder and
Ernst 2011).
There are two main pharmacological anti-selectin strategies: the
direct disruption of the selectin/selectin-ligand interaction with a
selectin antagonist (Binder and Ernst 2011), and the reduction of
cell surface levels of functional PSGL-1, the main selectin ligand.
Structurally, PSGL-1 is a homodimer composed of two heavily
O-glycosylated 120-kDa monomers (Wilkins et al. 1996, reviewed
in Moore 1998). The ﬁrst 19 amino acids of PSGL-1, which are suf-
ﬁcient for high-afﬁnity binding of PSGL-1 to P-selectin, include both
a tyrosine sulfation motif (Sako et al. 1995) and an O-glycosylation
site at Threonine-16 (Goetz et al. 1997). The tetrasaccharide Sialyl
Lewis X (sLeX, Fig. 1) is present as a terminal epitope on a signiﬁ-
cant proportion of O-glycans in this position, and is essential for
selectin-binding of PSGL-1 (Wilkins et al. 1996; Somers et al. 2000).
Several glycomimetics, such as GMI-1070 (Egger et al. 2013; Wun
et al. 2014; Telen et al. 2015) and bimosiamose (Beeh et al. 2006;
Kirsten et al. 2011), have been clinically successful as pan-selectin
antagonists in a range of therapeutic areas (Ernst and Magnani
2009). Inhaled bimosiamose has shown modest clinical efﬁcacy in
subjects with allergen-induced asthma following allergen challenge
(Beeh et al. 2006), as well as in a Phase-II trial in patients with
COPD (Kirsten et al. 2011). More recently, GMI-1070 was shown
to successfully reduce vaso-occlusive events in a Phase-II study of
patients with sickle cell disease (Telen et al. 2015). While these
results have provided clinical proof-of-concept for the therapeutic
value of an anti-selectin strategy, chemical pan-selectin antagonists
tend to be relatively large molecules, due to the shallow nature of
the P-selectin ligand-binding site (Somers et al. 2000). This can lead
to poor pharmacokinetics and very likely precludes p.o. administra-
tion. Bimosiamose, for example, has a molecular weight of 867, and
requires mandatory administration by inhalation.
An alternative approach to the direct disruption of the P-selectin/
PSGL-1 interaction with selectin antagonists is the reduction of cell
surface levels of functional PSGL-1. This can be achieved, e.g., by
inhibiting the biosynthesis of its functionally relevant glycans, in
particular sLeX. In unstimulated cells, inhibition of sLeX biosyn-
thesis has been accomplished with metabolic inhibitors and sub-
strate decoys for glycosyltransferases that affect galactosylation
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Fig. 1. (A) Structure of the PSGL-1 glycan epitope, including the terminal sLeX tetrasaccharide, and the LacNAc repeat unit connecting it to protein. Arrows indi-
cate the linkages generated by the galactosyltransferase β-1,4-GalT. (B) Chemical structures of inhibitors 1–3. The synthetic 5-(5-formylthien-2-yl) substituent is
shown in red. This ﬁgure is available in black and white in print and in color at Glycobiology online.
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(Sarkar et al. 1995; Brown et al. 2009), sialylation (Rillahan et al.
2012), fucosylation (Rillahan et al. 2012; Zandberg et al. 2012;
Belcher et al. 2015) or incorporation of N-acetylglucosamine
(Marathe et al. 2010; Barthel et al. 2011). Reducing the cell surface
levels of functional PSGL-1 offers at least three important advan-
tages over the direct disruption of the P-selectin/PSGL-1 interaction:
ﬁrstly, reduced levels of cell surface PSGL-1 will affect adhesion pro-
cesses mediated by all selectins, thus overcoming potential oper-
ational redundancy between individual selectins. Secondly, the levels
of PSGL-1 on the cell surface can be reduced by inhibition of PSGL-
1 biosynthetic enzymes. This can be achieved with classical, drug-
like small molecules that are orally bioavailable, in contrast to
selectin antagonists. Thirdly, and perhaps most importantly, as the
expression of PSGL-1 is upregulated during inﬂammation (Carlow
et al. 2009), a PSGL-1 biosynthesis inhibitor may allow the discrimin-
ation between PSGL-1 expression under physiological and pro-
inﬂammatory conditions. Such a discrimination, which is not possible
with a selectin antagonist, may selectively reduce the pro-inﬂammatory
effects of PSGL-1, but have only a limited effect on the constitutive cell
surface levels of PSGL-1 that are required for normal host defense,
resulting in a favorable safety proﬁle.
Previous studies with metabolic inhibitors and substrate decoys
have all been concerned with basal PSGL-1 and/or sLeX expression
in unstimulated cells (Sarkar et al. 1995; Brown et al. 2009;
Marathe et al. 2010; Barthel et al. 2011; Rillahan et al. 2012;
Zandberg et al. 2012; Belcher et al. 2015). Whether a small molecu-
lar weight inhibitor may be able to discriminate between the cell sur-
face presentation of PSGL-1 under basal and pro-inﬂammatory
conditions has, to the best of our knowledge, not been investigated
to date. It was the main goal of the present study to explore this
exciting possibility. We have established a ﬂow cytometry protocol
to study the cell surface levels of PSGL-1 on CD14+ human periph-
eral blood mononuclear cells (hPBMCs) from healthy donors, both
in the absence and presence of a pro-inﬂammatory stimulus (IL-1β).
We have used this assay to investigate the effects of a new class of
glycosyltransferase (GT) inhibitors, exempliﬁed by compound 1
(Fig. 1), on the levels of cell surface PSGL-1 in basal and IL-1β-
induced hPBMCs. Compound 1 is a derivative of the natural galac-
tosyltransferase (GalT) donor substrate UDP-galactose (UDP-Gal)
and a broad-spectrum GalT inhibitor (Pesnot et al. 2010; Descroix
et al. 2012; Jørgensen et al. 2013; Tedaldi et al. 2014). GalT inhibi-
tor 1 and the related compounds 2 and 3 were chosen for this study,
as the biosynthesis of functional, sLeX-decorated PSGL-1 requires
several GTs, including β-1,4-GalT (Fig. 1). β-1,4-GalT catalyzes
the transfer of D-galactose from a UDP-Gal donor to a terminal
N-acetyl-D-glucosamine (GlcNAc) residue on the acceptor (Sperandio
2006). The enzyme is required for the biosynthesis of not only the
sLeX epitope on PSGL-1, but also the LacNAc linker, which con-
nects sLeX to the protein backbone (Fig. 1). β-1,4-GalT is a particu-
larly interesting target for the selective intervention with PSGL-1
levels under pro-inﬂammatory conditions, as its expression is upre-
gulated in inﬂammation (Qian et al. 2007). All three compounds
reduce the cell surface presentation of PSGL-1 in a concentration-
dependent manner in IL-1β-stimulated cells, but not in resting cells.
Additional experiments, including selectivity, cell uptake and stabil-
ity experiments, suggest that these compounds may have an intracel-
lular mode of action, and are probably acting on sLeX biosynthesis.
This is the ﬁrst report on the cellular activity of this new class of GT
inhibitors. Our ﬁndings open new avenues for intervention with cell
surface levels of PSGL-1 and subsequent function, and may have dir-
ect implications for novel anti-inﬂammatory drug development.
Results
Time course of cell surface PSGL-1 levels on hPBMCs
It is known that, following stimulation of hPBMCs with a range of
pro-inﬂammatory stimuli, PSGL-1 undergoes a time-dependent pro-
cess of shedding and re-synthesis (Davenpeck et al. 2000; Marsik
et al. 2004). In order to identify the optimal time point for inhibitor
studies, we ﬁrst examined the levels of PSGL-1 on the cell surface of
CD14 positive (CD14+) hPBMCs at 0, 1, 24 and 48 h. We studied
cell surface PSGL-1 levels both on unstimulated hPBMCs (constitu-
tive PSGL-1 expression), and on hPBMCs stimulated with the pro-
inﬂammatory cytokine IL-1β at either 10 or 100 ng/mL. Cell surface
PSGL-1 was detected by ﬂow cytometry with the monoclonal mouse
anti-hPSGL-1-PE-conjugated antibody CD162 (clone KPL-1).
CD162/KPL-1 recognizes the N-terminus of PSGL-1 (Snapp et al.
1998), although there is some uncertainty regarding the exact epi-
tope. It has been suggested that the CD162/KPL-1 epitope comprises
amino acid residues 5–11 (YEYLDYD), including a consensus tyro-
sine sulfation motif (Snapp et al. 1998), but not the sLeX glycan
(Marathe et al. 2010), despite the close proximity of residues 5–11
to the O-glycosylation site at Threonine-16. To quantify the changes
in cell surface PSGL-1 levels, we determined both the population of
CD14+ cells displaying PSGL-1 (in % of the total population) and
the average cell surface levels of PSGL-1 per cell (as indicated by
mean ﬂuorescence intensity, MFI).
At 0 h, almost the entire population of CD14+ hPBMCs
(93.9 ± 4.9%, n = 2) displayed cell surface PSGL-1 constitutively
(Fig. 2 and Table I). Over the 48-h incubation period, the size of this
PSGL-1-presenting population ﬂuctuated, both in unstimulated and
IL-1β-treated cells (Fig. 2E). A maximal reduction to 71.8 ± 4.5%
was observed for CD14+ cells presenting PSGL-1 constitutively at
the 48 h timepoint (Table I). MFI readings showed a clear time-
dependent decrease of constitutive PSGL-1 levels on CD14+ cells
after both 24 h and 48 h incubation, by 62.5 ± 19.3% and
60.3 ± 2.8%, respectively (Fig. 2F and Table I). At 48 h, IL-1β-sti-
mulated hPBMCs appeared to recover the levels of cell surface
PSGL-1 back to those observed at 0 h, whereas unstimulated
hPBMCs had no such recovery (Fig. 2F and Table I). Thus, cell sur-
face levels of PSGL-1 on hPBMCs treated with IL-1β exceeded those
on unstimulated cells by approximately 2.5-fold (10 ng/mL IL-1β:
2.4 ± 0.6 fold; 100 ng/mL IL-1β: 2.7 ± 0.02 fold; Fig. 2F and
Table I).
Despite the restricted number of hPBMC donors, these initial
results suggested strongly that longer incubation times increase the
window between constitutive and IL-1β-induced PSGL-1 cell surface
levels. To maximize cell surface levels of PSGL-1 after shedding and
recovery, we therefore extended this preliminary time course to 72 h
post IL-1β stimulation. We found that 10 ng/mL IL-1β signiﬁcantly
increased cell surface levels of PSGL-1 by approximately 4-fold
(4.1 ± 0.4) compared to unstimulated CD14+ hPBMCs after 72 h
incubation (P < 0.0001, Fig. 3). The MFI was 22.0 ± 3.1 in
unstimulated hPBMCs, and 66.6 ± 5.2 in IL-1β-stimulated cells.
These conditions therefore provided an appropriate model and time-
frame to investigate inhibitors of IL-1β-induced PSGL-1 levels on
the cell surface of hPBMCs.
Effects of compound 1 on the cell surface levels of
PSGL-1 on hPBMCs
Next, we investigated the effect of compound 1, at a single concen-
tration, on the cell surface levels of PSGL-1. hPBMCs were
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incubated with 1mM compound 1 for 1 h, before cells were treated
with either media alone or 10 ng/mL IL-1β and further incubated for
0, 24, 48 or 72 hours. There was no signiﬁcant inhibitory effect of
compound 1 on the percentage of monocytes displaying PSGL-1
(Fig. 4A). MFI readings showed a maximal IL-1β-induced increase
in PSGL-1 levels, by 2.5-fold, at 72 h compared to unstimulated
levels (Fig. 4B, Table II). In the presence of compound 1, this
response was signiﬁcantly decreased by 74.7 ± 6.8%, back to the
basal levels observed at 0 h. Compound 1 also inhibited IL-1β-
induced cell surface PSGL-1 presentation by 40% and 53% at 24 h
and 48 h, respectively. These data demonstrate that 1 mM of com-
pound 1 reduces IL-1β-induced levels of PSGL-1 on the cell surface
of CD14+ hPBMCs at all time points examined. In contrast, the
MFI of PSGL-1 levels on resting hPBMCs was not signiﬁcantly dif-
ferent in the presence or absence of compound 1, with the exception
of a small, albeit signiﬁcant, decrease at 24 h (8.4 ± 1.4 vs.
16.0 ± 2.9, P < 0.05) (Fig. 4B).
Effects of compound 1 on the cell surface levels of
sLeX on hPBMCs
In vitro, compound 1 is a potent, broad-spectrum inhibitor of GalTs
(Pesnot et al. 2010; Descroix et al. 2012; Tedaldi et al. 2014),
including β-1,4-GalT, which is required for sLeX biosynthesis
(Fig. 1). To assess the effect of compound 1 on global sLeX presen-
tation on hPBMCs, we repeated our inhibition experiments using an
antihuman-sLeX (CD15s) antibody. Incubation with compound 1
did not affect the percentage of CD14+ hPBMCs displaying sLeX
on either IL-1β-stimulated cells or controls (Fig. 5A). However, after
72 h incubation, a signiﬁcant decrease in cell surface levels of sLeX
(MFI) was observed for hPBMCs treated with both IL-1β and com-
pound 1 (1 mM), compared to cells treated with IL-1β only
(P < 0.01, Fig. 5B). This suggests that, as expected for a GalT inhibi-
tor, compound 1 reduces global sLeX presentation on hPBMCs.
Epitope speciﬁcity of the anti-sLeX and anti-PSGL-1
monoclonal antibodies
To conﬁrm the epitope speciﬁcity of the anti-sLeX monoclonal anti-
body for the α-2,3-sialosylated form of lacto-N-fucopentaose III (i.e.
sLeX), we removed cell surface sialic acid by treating hPBMCs with
neuraminidase prior to addition of antibody. As expected, neur-
aminidase (0.025–0.1 U/mL) treatment prevented sLeX antibody
recognition (Fig. 6A). In contrast, it had no signiﬁcant effect on the
ability of the anti-human PSGL-1 antibody CD162/KPL-1 to recog-
nize its epitope in the same cells, whether stimulated with IL-1β or
not (Fig. 6B). This suggests that the CD162/KPL-1 epitope does not
include sLeX. This result is in keeping with the ﬁndings of Marathe
and coworkers (Marathe et al. 2010) that neuramidinase treatment
Fig. 2. Characterization of IL-1β-induced PSGL-1 cell surface levels on human
monocytes. (A) Human mononuclear cells were isolated from healthy donors
(n = 2) and incubated with anti-CD14-FITC to identify the monocyte population
by ﬂow cytometry (region R1). (B) CD14+ monocytes incubated with isotype
control IgG-PE to reveal background ﬂuorescence. (C) Scatter graph revealing
the percentage of resting CD14+ monocytes displaying PSGL-1 (region R2).
(D) Representative histogram of CD14+ monocytes and mean ﬂuorescence
intensity of PSGL-1 levels (anti-PSGL-1-PE). hPBMCs were either treated with
media alone (white bar), 10 ng/mL recombinant human IL-1β (gray bar), or 100
ng/mL IL-1β (black bar) for 0–48 hr. Cells were harvested and co-stained with
PE CD162, FITC CD14 and isotype matched controls. (E) Percentage of CD14+
monocytes displaying PSGL-1. (F) Mean ﬂuorescent intensity (MFI) of cell sur-
face PSGL-1 levels on monocytes. Data represent mean ± SEM. This ﬁgure is
available in black and white in print and in color at Glycobiology online.
Table I. Changes in cell surface levels of PSGL-1 over time
Time (h) Treatment PSGL-1
levels
Unstimulated IL-1β 10 ng/mL IL-1β 100 ng/mL
0 93.9 ± 4.9 – – %
35 ± 7.9 – – MFI
24 75.5 ± 15.5 83.1 ± 6.6 83.7 ± 5.9 %
11.6 ± 3.8 17.0 ± 5.3 17.5 ± 7.6 MFI
48 71.8 ± 0.5 82.9 ± 0.5 84.5 ± 5.5 %
14.1 ± 4.1 30.9 ± 1.1 38.3 ± 10.9 MFI
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does not affect the detection of PSGL-1 levels on HL-60 cells by the
same CD162/KPL-1 antibody used in our study.
Effects of compound 1 on the cell surface levels of
CD14, CD11b and CCR2 on hPBMCs
In order to explore its target selectivity, we investigated the effect of
compound 1 on the levels of three cell surface proteins other than
PSGL-1: CD11b, our monocyte marker CD14, and the chemokine
receptor CCR2, a G-protein-coupled receptor for monocyte chemo-
attractant protein-1. Like PSGL-1, CD11b is decorated with sLeX
moieties (Zen et al. 2007). 10 ng/mL IL-1β induced a 2.2-fold
increase in cell surface CD11b levels after 72 h incubation (Fig. 7A).
This response was signiﬁcantly inhibited by 1mM compound 1
back to constitutive levels (Fig. 7A, P < 0.05, n = 10). In contrast to
CD11b, cell surface levels of CD14 and CCR2 were not increased
by IL-1β-treatment (Fig. 7B & C). Moreover, compound 1 had no
effect upon cell surface levels of either CD14 (Fig. 7B, n = 11, 72 h),
or CCR2 (Fig. 7C, n = 4, 24 h), neither in the presence nor absence
of IL-1β. Collectively, these data suggest that compound 1 inhibits
pathways associated with the cell surface presentation of PSGL-1,
sLeX and CD11b, but not of CD14 and CCR2.
Concentration-dependent reduction of cell surface
levels of PSGL-1 by compounds 1–3
In order to obtain a more quantitative measure of its inhibitory
activity toward PSGL-1 cell surface presentation, in the presence
and absence of IL-1β, we determined full concentration-response
curves for compound 1 (1 nM–1mM) in our PSGL-1 inhibition
assay. In the absence of inhibitor, 10 ng/mL IL-1β induced a 3.4-fold
increase in PSGL-1 levels compared to unstimulated cells (Fig. 8A).
Compound 1 inhibited the IL-1β-induced cell surface presentation
of PSGL-1 in a concentration-dependent manner with an IC50 of
174 µM (n = 5–9, P < 0.0001, Fig. 8A), but showed no inhibition of
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Fig. 3. IL-1β-induced PSGL-1 cell surface levels on human monocytes. Human monocytes were isolated from healthy donors (n = 17) and incubated in the pres-
ence (black bar) and absence (white bar) of 10 ng/mL recombinant human IL-1β for 72 h. Cells were harvested and co-stained with PE CD162, FITC CD14 and iso-
type matched controls. (A) Represents mean ﬂuorescent intensity (MFI) values in unstimulated and IL-1β-treated (10 ng/mL) cells and (B) fold change in PSGL-1
levels upon stimulation with IL-1β, relative to unstimulated (media alone) control values. IL-1β signiﬁcantly induced a 4.0 ± 0.4 fold increase in PSGL-1 cell sur-
face levels (***P < 0.0001, students paired t test, n = 21). Data represent mean ± SEM from 21 independent experiments using monocytes isolated from 17
human donors (10M/7F).
Fig. 4. Effect of compound 1 (1mM) on PSGL-1 cell surface levels. Monocytes from whole blood were incubated for 0, 24, 48 and 72 hours with or without IL-1β
(10 ng/mL), and with or without compound 1. Samples were analyzed using ﬂow cytometry. Graphs show (A) the percentage of mononuclear cells displaying
cell surface PSGL-1, (B) the mean ﬂuorescence intensity (MFI) of PSGL-1 cell surface levels. Data are expressed as mean ± SEM (n = 4–6). *P < 0.01 and
**P < 0.05 between IL-1β-stimulated groups.
Table II. IL-1β-induced presentation of cell surface PSGL-1 in the
presence and absence of compound 1
Time (h) Treatment PSGL-1 levels
IL-1β IL-1β + cmpd 1
0 16.7 ± 6.6 16.7 ± 6.6 MFI
24 13.9 ± 2.1 8.4 ± 1.3 MFI
48 22.2 ± 3.7 10.4 ± 2.1 MFI
72 44.2 ± 10.0 13.8 ± 4.1 MFI
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basal PSGL-1 levels (Fig. 8B). Interestingly, however, at sub-
maximal concentrations compound 1 did alter basal PSGL-1 levels,
with a bell-shaped concentration-response curve having a maximal
3.56 ± 0.69 fold increase at 100 µM (n = 5–9, P < 0.0001, Fig. 8B)
compared to unstimulated monocytes. Monocyte cell viability by
trypan blue exclusion was 100% in the presence of 0.5mM com-
pound 1.
We also investigated the effect of UDP-GlcNAc derivative 2 and
UMP derivative 3 (Fig. 1) on PSGL-1 cell surface presentation under
the same conditions. Compound 2 is a congener of compound 1,
possessing a different sugar (1: D-galactose; 2: N-acetyl-D-glucosa-
mine), while compound 3 is a possible breakdown product of both
1 and 2. In the absence of inhibitor, 10 ng/mL IL-1β induced an
increase in PSGL-1 levels compared to unstimulated cells, by 3.6-
fold (compound 2, Fig. 8C) and 2.7-fold (compound 2, Fig. 8E),
respectively. Both compounds 2 and 3 showed a similar proﬁle as
their parent compound 1, and reduced IL-1β-induced PSGL-1 levels
in a concentration-dependent manner, with an IC50 of 77 µM (com-
pound 2, n = 7, P < 0.0001, Fig. 8C) and 343 µM (compound 3,
n = 9, P < 0.0001, Fig. 8E), respectively. While neither compound 2
or 3 inhibited basal PSGL-1 levels, both led to a bell-shaped
response, with a maximal increase of 3.5 ± 1.0 fold at 50 µM (com-
pound 2, n = 7, P < 0.0001, Fig. 8D) or 2.3 ± 0.3 fold at 100 µM
(compound 3, n = 9, P < 0.0001, Fig. 8F), compared to unstimu-
lated monocytes. Monocyte cell viability was 100% in the presence
of both 0.5 mM compound 2 and 0.5mM compound 3.
Stability tests and cell uptake of inhibitors
In order to assess the stability of UDP-sugar 1 and UMP derivative 3
under the conditions of the PSGL-1 inhibition assay, we carried out
stability tests in the presence of hPBMCs. In these experiments, com-
pound 1 or 3 (at 1mM) was incubated for 1–24 h with the hPBMC
suspension used in the PSGL-1 inhibition assay. Experiments at each
time point were carried out in quadruplicate, with two different
batches of hPBMCs. The cell suspension was centrifuged, the super-
natant (representing the extracellular fraction of inhibitor) and cell
pellet (representing the intracellular fraction of inhibitor) were sepa-
rated, and the cells of the pellet were lysed with lysis buffer. Both
the supernatant and the cell lysate were analyzed by RP-HPLC,
using a gradient of 0.05M phosphate buffer (pH 8) against metha-
nol, which allowed complete separation of compound 3 (retention
time: 6.6min) and compound 1 (retention time: 7.8min). HPLC
traces of the samples incubated with compound 3 showed no other
components at UV detection wavelengths of 210, 230, 254 and 280
nm. This result suggests that the UMP derivative 3 is stable in the
presence of the hPBMC suspension. In contrast, samples incubated
with compound 1 contained between 15% (extracellular fraction)
and 30% (intracellular fraction) of 3 over the course of the incuba-
tion period (Fig. 9). No other degradation products of compound 1
were observed by HPLC. Maximal levels of the hydrolysis product 3
(extracellular fraction: 15%, intracellular fraction: 30%) were
observed already at the ﬁrst time point, and did not increase signiﬁ-
cantly over the course of the incubation period. These concentration
levels of compound 3 are comparable to those observed in a control
experiment at t = 0 h (Fig. 9). This suggests that the observed deg-
radation of compound 1 into compound 3 may happen largely dur-
ing the work-up step of the stability assay.
Finally, we used the results from the stability experiments for a
semi-quantitative assessment of the cellular uptake of compounds 1
and 3 by hPBMCs (Fig. 10). From the concentrations of compounds
1 and 3 in the cell pellet, after centrifugation and lysis, we deter-
mined the intracellular proportion of compounds 1 and 3 as a per-
centage of the total concentration used (1 mM). The concentration
of 5-FT UDP-Gal 1 in the cell pellet is based on the total peak area
for both intact 1 and its degradation product 3 (see Fig. 9). Our
HPLC data indicate that approximately 0.5–1% of a 1mM stock
solution of compound 1 are taken up by hPBMCs over 24 h
(Fig. 10). Interestingly, the intracellular levels of compound 1 did
not change signiﬁcantly over the course of the incubation period.
A similar cell uptake proﬁle was also observed for the UMP deriva-
tive 3 (Fig. 10).
Discussion
In this study, we have determined the constitutive and IL-1β-induced
cell surface levels of PSGL-1 on human monocytes by ﬂow cytome-
try, in order to identify suitable conditions for the evaluation of inhi-
bitors. In IL-1β-stimulated cells, initial PSGL-1 shedding occurred
on the cell surface between 1 and 24 hours after IL-1β stimulation,
Fig. 5. Effect of compound 1 (1mM) on sLeX cell surface levels. Monocytes
from whole blood were incubated for 72 hours with or without IL-1β (10 ng/
mL), and with or without compound 1. Samples were analyzed using ﬂow
cytometry. Graphs show (A) the percentage of CD14+ cells displaying cell
surface sLeX; (B) the mean ﬂuorescence intensity (MFI) of sLeX levels. Data
are expressed as mean ± SEM (n = 4–5). **P < 0.01 between IL-1β-stimulated
groups. ns indicates not signiﬁcant.
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followed by PSGL-1 recovery from 24 to 72 hours. The maximal
window between basal and IL-1β-induced PSGL-1 cell surface pres-
entation was observed after 72 h, suggesting that this time point is
best suited for the identiﬁcation and evaluation of chemical inhibi-
tors of IL-1β-induced PSGL-1 cell surface levels. PSGL-1 is highly
glycosylated (Wilkins et al. 1996; Somers et al. 2000) and requires
the expression of the glycan epitope sLeX for full functional activity
(reviewed in Moore 1998). We hypothesized that inhibition of one
or more of the GTs required for sLeX biosynthesis (Fig. 1) may
reduce the cell surface levels of fully glycosylated PSGL-1. To test
this hypothesis, we investigated the effects of the known broad-
spectrum GalT inhibitor 1 (Pesnot et al. 2010; Descroix et al. 2012;
Tedaldi et al. 2014) as well as the closely related compounds 2 and 3
(Fig. 1) in our assay.
Interestingly, all three test compounds reduced the cell surface
levels of PSGL-1 on IL-1β-stimulated hPBMCs, but not on resting
cells, as detected by ﬂow cytometry (Fig. 8). The most potent inhib-
ition was observed with the UDP-N-acetylglucosamine (UDP-
GlcNAc) derivative 2. There was a signiﬁcant difference in inhibi-
tory response between compounds 1 and 2 at 100 µM, and between
compounds 2 and 3 at 100 µM, 250 µM and 1mM, (p < 0.05,
Fig. 8), while the differences between the inhibitory response of
compounds 1 and 3 were not statistically signiﬁcant. These results
indicate that the presence of a sugar (1: D-galactose; 2: N-acetyl-D-
glucosamine) is beneﬁcial for activity in this class of donor-based
GT inhibitors, while the UMP scaffold alone, as in compound 3,
leads to only modest activity. The superiority of the UDP-sugars
1 and 2 over the corresponding UMP derivative 3 is in keeping
with well-known structure-activity trends for the inhibition of GTs
by sugar-nucleotides and their corresponding mononucleotides.
In conjunction with our stability and cell uptake results, the superior
activity of compounds 1 and 2 also suggests that it is the complete
Fig. 6. Neuraminidase treatment. Monocytes from whole blood were incubated for 72 hours with or without IL-1β (10 ng/mL). Samples were treated with or with-
out neuraminidase (0.025–0.1 U/mL) and analyzed using ﬂow cytometry. Graphs show (A) the MFI of sLeX cell surface levels, and (B) the MFI of PSGL-1 cell sur-
face levels. Data are expressed as mean ± SEM (n = 4–6).
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UDP-sugars, not the potential breakdown product 3, that are the
active agents. However, a more complex mechanism involving the
breakdown within cells of 1 and 2 into 3, followed by re-synthesis
to one or more UDP-sugars, cannot be excluded.
At present, our results do not provide a mechanistic explanation
for the observed reduction of IL-1β-induced cell surface levels of
PSGL-1 by compounds 1–3. We propose a hypothesis based on the
observation that GalT inhibitor 1 reduces not only the global
presentation of the glycan epitope sLeX on the surface of IL-1β-sti-
mulated hPBMCs (Fig. 5), but also the IL-1β-induced presentation
of CD11b, another cell surface glycoprotein decorated with sLeX
(Fig. 7). Given the importance of sLeX for PSGL-1 function, this
may suggest a link between the effects of compound 1 on PSGL-1
levels on the one hand, and sLeX on the other. Inhibition of sLeX
biosynthesis alone cannot, however, account for the observed reduc-
tion in IL-1β-induced cell surface levels of PSGL-1 in the presence of
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Fig. 8. Compounds 1 (panels A & B), 2 (panels C & D) and 3 (panels E & F) inhibit IL-1β-induced PSGL-1 cell surface levels on human monocytes, and potentiate
basal PSGL-1 presentation. Human monocytes were isolated from healthy donors (1: n = 9; 2: n = 7; 3: n = 9) and incubated in the presence (black bar) or
absence (white bar) of 10 ng/mL recombinant human IL-1β for 72 h. Cells were harvested and co-stained with PE CD162, FITC CD14 and isotype-matched con-
trols. Concentration-response curves in panels A, C and E show PSGL-1 levels in %, relative to maximal PSGL-1 levels (***P < 0.0001, one-way ANOVA; 1:
n = 9; 2: n = 7; 3: n = 9), upon stimulation with 10 ng/mL IL-1β and incubation with inhibitor for 72 h (A: 1; C: 2; E: 3). IC50 values extracted from concentration-
response curves in panels A, C and E are 174 µM (for compound 1), 77 µM (for compound 2) and 343 µM (for compound 3). Concentration-response curves in
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Data for compound 1 represent mean ± SEM from 11 independent experiments using monocytes isolated from 9 human donors. Data for compound 2
represent mean ± SEM from 7 independent experiments using monocytes isolated from 7 human donors. Data for compound 3 represent mean ± SEM from 9
independent experiments using monocytes isolated from 9 human donors.
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compound 1. Our neuraminidase experiments show, in keeping
with previous reports by others (Marathe et al. 2010), that the
CD162/KPL-1 antibody used in our assay does not require the pres-
ence of sLeX on PSGL-1 for epitope binding. Modiﬁcations to the
structure of sLeX alone would therefore not be detected by the
CD162/KPL-1 antibody. This implies that compound 1 does not
just alter the structure of sLeX, on PSGL-1 and other glycoproteins,
but genuinely reduces the levels of cell surface PSGL-1 induced by
IL-1β. As a possible explanation, we propose that inhibition of sLeX
biosynthesis by compound 1 may compromise the trafﬁcking of
PSGL-1 to the cell surface. Although a role speciﬁcally for sLeX in
glycoprotein trafﬁcking has not previously been reported, it is well
known that glycosylation affects the intracellular trafﬁcking of gly-
coproteins and can be manipulated with glycosylation inhibitors
(Huet et al. 2003). In preliminary experiments, we have indeed
observed that compound 1 does not only reduce IL-1β-induced
PSGL-1 levels on the cell surface, but also the intracellular levels of
PSGL-1 (unpublished results). These initial ﬁndings appear to be
consistent with the trafﬁcking hypothesis, but further, quantitative
experiments will be required to clarify this.
It is important to note that this mechanism is, at present, hypothet-
ical, and that alternative mechanistic explanations for the observed
effects of compounds 1–3 on IL-1β-induced cell surface presentation
of PSGL-1 in hPBMCs are conceivable. The lower detection levels of
cell surface PSGL-1 by the KPL-1 antibody in the presence of inhibitor
may, for example, reﬂect a more general modiﬁcation of galactose-
containing glycan structures and not just the absence of the sLeX epi-
tope. Davey and coworkers have recently identiﬁed galactosyltransfer-
ase 4 as a major control point for glycan branching in N-linked
glycosylation (McDonald et al. 2014). A broad-spectrum GalT inhibi-
tor such as compound 1 (Pesnot et al. 2010) would therefore be
expected to substantially alter the structure and composition of
eukaryotic N-glycans. The inhibition proﬁle of compound 1 toward
the four different cell surface glycoproteins investigated in this study
narrows down potential intervention points (Table III). Compound 1
is not a general inhibitor of protein N-glycosylation in the endoplas-
mic reticulum, as evidenced by the lack of inhibition toward CD14
and CCR2, which are both N-glycosylated (Table III). Neither is com-
pound 1 a general inhibitor of O-glycan core structures, as it reduces
the cell surface presentation of both PSGL-1, which is O-glycosylated,
and CD11b, which is not (Table III). Taken together, this proﬁle sug-
gests that compound 1 alters not the core structure, but the antennae
and/or terminal epitopes (e.g. sLeX) of affected glycans, possibly by
inhibiting one or more GTs resident in the Golgi.
Our results in IL-1β-treated hPBMCs are also consistent with a
possible effect of our inhibitors on the IL-1 receptor (IL-1R). It is
known that glycosylation of IL-1R is required for optimal binding
of IL-1 (Mancilla et al. 1992). If the glycan structure on IL-1R was
compromised as a result of the activity of inhibitors 1–3, this may
attenuate the stimulation of hPBMCs by IL-1β and result in a
reduced presentation of PSGL-1, as observed.
A prerequisite for all three of these hypothetical mechanisms is
the cellular uptake of the inhibitors in stable form. In biological
media, sugar-nucleotides such as compounds 1 and 2 can be subject
to both chemical and enzymatic hydrolysis, due to the presence of
several labile bonds, including the glycosidic linkage and the pyro-
phosphate bond (Huhta et al. 2010). Under the standard hydrolytic
pathway for UDP-sugars (Huhta et al. 2010), the primary degrad-
ation product of compound 1 would be expected to be UMP deriva-
tive 3. Results from our stability assay indicate that, while
Fig. 9. Hydrolysis of 5-FT UDP-Gal (1) into 5-FT UMP (3) upon incubation with
hPBMCs. Cells were incubated with 1 (1mM) over 24 h and samples taken at
different time points. The relative amounts of intact 1 and its metabolite 3 are
shown as percentages of the total amount (1 + 3) in, respectively, the super-
natant (extracellular fraction, from supernatant), or the cell pellet after centrifu-
gation and lysis (intracellular fraction, from cell pellet). Values are mean ± SEM
from 4 independent experiments using hPBMCs from 2 human donors.
Fig. 10. Cellular uptake of 5-FT UDP-Gal (1) and 5-FT UMP (3) into hPBMCs.
Cells were incubated separately with either 1 (1mM) or 3 (1mM) over 24 h
and samples taken at different time points. The concentrations of 1 and 3 in
the cell pellet, after centrifugation and lysis, are shown as percentages of the
total concentration used (1mM). The concentration for 5-FT UDP-Gal 1 is
based on the total peak area for both intact 1 and its degradation product 3
(see Fig. 9). Values are mean ± SEM from 4 independent experiments using
hPBMCs from 2 human donors.
Table III. Glycosylation proﬁle of different cell surface glycoproteins, and inhibition of their cell surface levels in hPBMCs by compound 1
Glycoprotein Inhibition by cmpd 1 sLeX O-glycans N-glycans
PSGL-1 Yes Yes (Somers et al. 2000) Yes (Somers et al. 2000) Yes (Somers et al. 2000)
CD11b Yes Yes (Zen et al. 2007) No (Sastre et al. 1986) Yes (Sastre et al. 1986)
CD14 No not known Yes (Nilsson et al. 2009) Yes (Meng et al. 2008)
CCR2 No not known No (Preobrazhensky et al. 2000) Yes (Preobrazhensky et al. 2000)
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compound 3 itself is stable in hPBMC suspension over 24 h, com-
pound 1 is indeed partly hydrolyzed into compound 3, both intra-
and extracellularly (Fig. 9). The unusual time course of degradation
suggests, however, that the hydrolysis of compound 1 under the
conditions of our stability assay may happen largely during the
work-up step. Although it cannot be ruled out completely that UDP-
Gal derivative 1 is subject to some hydrolysis during the incubation
with hPBMCs, the results from the stability tests indicate that at
least 70–85% of intact compound 1 is present under the conditions
of the PSGL-1 inhibition assay. This suggests that the observed
PSGL-1 inhibitory effect of compound 1 is indeed due to the intact
UDP-sugar rather than its breakdown product 3.
We have previously exploited the ﬂuorescence emission of UDP-
sugar 1 to qualitatively investigate its cellular uptake by ﬂuorescence
microscopy (Descroix et al. 2012). The quantiﬁcation of the intra- and
extracellular concentrations of compounds 1 and 3 during the stability
experiments in the present study has allowed, for the ﬁrst time, a
quantitative assessment of the cellular uptake of compounds 1 and 3
by hPBMCs. Our HPLC data indicate that approximately 0.5–1% of
a 1mM stock solution of compound 1 are taken up by hPBMCs
over 24 h (Fig. 10). Interestingly, the intracellular levels of compound
1 did not change signiﬁcantly over the course of the incubation peri-
od. A similar cell uptake proﬁle was also established for the UMP
derivative 3 (Fig. 10). Given the charged nature of these molecules,
the limited cell penetration of compounds 1 and 3, even after pro-
longed incubation, is not surprising. Importantly, although the intra-
cellular concentrations of compound 1 in our experiments are low,
they are compatible with the hypothesis that compound 1 reduces
cell surface PSGL-1 levels through inhibition of an intracellular
GalT, e.g. β-1,4-GalT. In vitro, compound 1 inhibits recombinant
β-1,4-GalT with an IC50 value of 0.9 μM (Tedaldi et al. 2014). That
the IC50 value of compound 1 for cellular inhibition of PSGL-1
presentation on hPBMCs (174 μM) is more than 150-fold greater is
therefore consistent with its cell uptake being limited to approxi-
mately 1%.
While the inhibitory effect of compounds 1–3 on basal cell sur-
face levels of PSGL-1 was minimal, as desired, a modest increase in
PSGL-1 presentation was observed in resting cells at submaximal
inhibitor concentrations (Fig. 7). This effect disappeared at higher
concentrations, leading to a “bell-shaped” concentration-response
curve. A possible explanation for this unusual proﬁle may be that
in resting cells, low concentrations of compounds 1–3 may be able
to induce PSGL-1 presentation, but that at higher concentrations,
this effect is off-set by their inhibitory activity. The “bell-shaped”
curve may therefore represent the overlay of induction and inhib-
ition of PSGL-1 cell surface levels at different inhibitor concentra-
tions. It is important to note that neither this unusual activity
proﬁle in resting hPBMCs, nor the inhibitory effects toward
IL-1β-induced PSGL-1 presentation is caused by cytotoxicity, as
none of the compounds 1–3 showed any effect on cell viability in
the trypan blue assay up to 72 h.
Conclusion
We have investigated the effect of the GalT inhibitor 5-(5-
formylthien-2-yl) UDP-Gal 1, as well as the corresponding 5-
substituted derivatives of UDP-GlcNAc (2) and UMP (3), on cell
surface presentation of PSGL-1 on human monocytes. All three
compounds reduce IL-1β-induced cell surface PSGL-1 to basal levels,
in a concentration-dependent manner. Compound 1 also inhibits
IL-1β-induced presentation of CD11b, but not the cell surface levels
of CD14 and CCR2. Together with results from sLeX inhibition
experiments, this suggests that these inhibitors act on the cell surface
presentation of PSGL-1 via a sLeX-dependent pathway, possibly by
affecting glycan-dependent trafﬁcking of PSGL-1 to the cell surface.
It is important to note that, on the basis of our current data, this
proposed mechanism is hypothetical, and alternative mechanisms of
action cannot be ruled out, including e.g. more general modiﬁca-
tions of glycan structures or the incorporation of compound 3 into
RNA. The potency of compound 1 in inhibiting IL-1β-induced cell
surface PSGL-1 levels is limited by its low uptake into cells, and
increasing the cell penetration of compound 1 therefore represents
an obvious strategy for improving its cellular activity. Intriguingly,
under basal conditions, compounds 1–3 have a modest stimulatory
effect on PSGL-1 presentation at sub-maximal concentrations. This
may indicate that at low concentrations, they may actually induce
PSGL-1 presentation in resting cells. While compounds 1–3 them-
selves may therefore have limited potential for further development,
taken together, our results provide proof-of-concept that cell surface
levels of PSGL-1 under pro-inﬂammatory and basal conditions can
be differentially modulated with small molecules. These ﬁndings
therefore open new avenues for intervention of cell surface PSGL-1
levels and may have direct implications for anti-inﬂammatory drug
development.
Materials and Methods
Reagents
Compounds 1–3 were prepared as previously described (Pesnot et al.
2010; Tedaldi et al. 2012; Pesnot et al. 2013), puriﬁed by ion-
exchange and ion-pair chromatography, and used in their triethylam-
monium salt form. Human recombinant IL-1β was purchased from
eBioscience (Hatﬁeld, UK). All antibodies were obtained from BD
Biosciences (Oxford, UK) unless otherwise stated. PE-conjugated
mouse anti-human CD162 antibody (clone KPL-1, 556055), FITC-
conjugated mouse anti-human CD14 antibody (clone M5E2,
555397), PE-conjugated mouse anti-human CD11b/Mac-1 (clone
ICRF44, 555388), PE-conjugated mouse IgG2a, K Isotype control
antibody (clone G155-178, 555574), puriﬁed mouse anti-human
CD15s antibody (nonconjugated-anti-CD15s, 551344) and FITC-
conjugated goat anti-mouse IgG/IgM antibody (polyclonal, 555988).
Alexa Fluor 488 conjugated mouse anti-human CCR2 antibody (clone
# 48607, FAB151G) and Alexa Fluor 488 conjugated mouse IgG2B
isotype control antibody (clone 133303) were purchased from R&D
systems (Abingdon, UK). RPMI 1640 Medium with GlutaMAX™
and Penicillin-Streptomycin (Penstrep) was from Life Technologies
Gibco® (Paisley, UK). Bovine serum albumin, phosphate buffered
saline, sodium azide, formaldehyde, histopaque-1077 and neuraminid-
ase from Vibrio cholerae were from Sigma Aldrich (Dorset, UK).
Isolation of hPBMCs and treatments.
The study was approved by the national research ethics committee
at Guy’s and St Thomas’ Hospitals (10/H0807/99). Peripheral ven-
ous blood was collected from healthy donors into syringes contain-
ing 10% v/v ACD anticoagulant. After complete mixing, blood was
added to leucosep® tubes that contained pre-warmed Histopaque-
1077 under the barrier. The samples were centrifuged at 1000 g for
10min. Following centrifugation, mononuclear cells were separated
by density from platelets, plasma, granulocytes and red blood cells.
Monocyte layers were gently aspirated off and washed twice with
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media (RPMI-1640 medium with GlutaMAX™ supplemented with
2% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin) in a
5% CO2, humidiﬁed atmosphere at 37°C. Cell counts were per-
formed, and 0.4 × 106 cells were seeded into each well of a 96-well
plate. For IC50 experiments, cells were seeded between 1.0 and
2.0 × 106 cells/mL and pre-incubated with media in the presence and
absence of compounds (1 nM–1mM) for 1 h, followed by 10 ng/mL
IL-1β in the continued presence of compounds for up to 72 h at 37°C
and 5% CO2. Cells were harvested and analyzed by ﬂow cytometry.
For the 72 h experiments, cell viability to each compound (n = 3) was
examined using 0.4% Trypan Blue solution. An equal volume of trea-
ted cells and Trypan Blue solution was loaded onto haemacytometers,
and both viable and non-viable cells were counted. Viability (in %)
was calculated as the number of viable cells divided by the total num-
ber of cells (both viable and non-viable).
Flow cytometry
The cell surface levels of PSGL-1 (CD162), sLeX (CD15s), Mac1
(CD11b) and CCR2 were measured by ﬂow cytometry on an Epics
XL MCL instrument equipped with an air-cooled laser (488 nm,
15mW) and a Cytomics FC500 instrument (Beckman Coulter, Florida).
For cell surface immunostaining, cells (2 × 106 cells/mL) were centri-
fuged (1200 rpm, 5min, 4°C) and resuspended in FACS buffer (PBS
supplemented with 1% BSA and 5mM sodium azide). For neuramidi-
nase experiments, cells were prior ﬁxed with 4% paraformaldehyde.
Cells were immunostained for CD162 (1:25), CD15s (1:50), CCR2
(1:25), CD11b (1:25) and their respective isotype controls for 20–30
min at 4°C. FITC/PE-anti-CD14 (1:50) antibodies were used for the
measurement of the monocyte population. After incubation, cells were
washed twice with FACS buffer and analyzed directly. Samples labeled
with sLeX antibody were incubated with a secondary FITC-conjugated
Goat Anti-Mouse IgG/IgM antibody, washed again twice with FACS
buffer, and resuspended in FACS buffer prior to FACS analysis. 3000
gated cells were analyzed in each experiment with the Coulter System
II software, and the percentage and the mean ﬂuorescence intensity
(MFI) were used to quantify the responses. For Cytomics FC500, CXP
software was used to quantify responses.
Statistical analysis
All raw data (either MFI or % of cells) are presented as
mean ± SEM. Fold change data were collected from individual
donor treatments by normalizing to respective unstimulated controls
and presented as mean ± SEM experiments. Data for dose- and
time-dependency of PSGL-1 levels upon incubation of hPBMCs with
IL-1β for 0–72 h, including the effect of inhibitor 1 at 1mM, were
analyzed with one-way analysis of variance (ANOVA), followed
by Bonferroni’s multiple-comparisons test. Data for the effect of
compound 1 on PSGL-1 or sLeX levels at 72 h were analyzed using
two-way analysis of variance (ANOVA), followed by Bonferroni
post-test. All analyses were performed with GraphPad Prism and
IC50 curves for normalized data were generated by a four-parameter
sigmoidal model (version 5.0; GraphPad, San Diego, CA). A P value
less than 0.05 was considered signiﬁcant.
Stability tests
Incubation with inhibitors
On a 96-well microplate, 200 µL of hPBMC suspension at 2 × 106
cell/mL was added per well. Inhibitors 1 or 3 (ﬁnal concentration:
1mM) were added to individual wells and incubated for 1, 2, 3, 6
and 24 hours. Samples were collected and immediately centrifuged
at 1300 x g for 5 minutes. The supernatant (representing the extra-
cellular inhibitor fraction) was separated, freeze-dried and stored at
−80°C until quantiﬁcation. To the pellet (representing the intracellu-
lar inhibitor fraction), 185 µL of cold 0.5M PCA was added. The
sample was mixed, incubated on ice for 2 minutes and centrifuged
at 10,000 x g for 5 minutes. After centrifugation, the supernatant
was transferred to a new vial, and 42 µL of cold 2.5M KOH
in 1.5M K2HPO4 was added. The solution was incubated on ice for
2 minutes and centrifuged at 10,000 x g for 5 minutes. The super-
natant was ﬁltered through a 2 µm ﬁlter, and the ﬁlter membrane
was washed twice with 100 µL of ultra pure H2O. The ﬁltrate was
freeze-dried and stored at −80°C until quantiﬁcation. Each inhibitor
concentration was tested in quadruplicate.
Quantiﬁcation of inhibitor fractions
All samples (cell pellet or supernatant) were analyzed by reverse-phase
high performance liquid chromatography (RP-HPLC) on a Perkin
Elmer 200 machine equipped with a Supelcosil LC-18-T column
(5 µm, 25 cm × 4.6mm), an autosampler and a diode array detector.
Detection wavelengths: 254, 210, 230 and 280 nm. Reference wave-
length: 360 nm. Flow rate: 1.5mL/min. Gradient: 0.05M phosphate
buffer (pH 8) against methanol. Solvents were purchased from Fisher
Scientiﬁc and were of HPLC-grade quality. Extracellular samples were
dissolved in 90 µL of H2O (injection volume: 30 µL). Intracellular
samples were dissolved in 90 µL of H2O (24 h, injection volume: 30
µL), 60 µL of H2O (6 h, injection volume: 60 µL), or 30 µL of H2O (1,
2 and 3 h, injection volume: 30 µL). The smaller total volume was
required for the intracellular samples because of the relatively low
concentration of inhibitor. Retention times: 1 – 7.8min, 3 – 6.6min.
Data analysis
Samples were quantiﬁed based on Total Peak Area (TPA) in the
respective HPLC chromatogram. In the presence of hPBMCs, com-
pound 1 is hydrolyzed into compound 3 both intra- and extracellu-
larly. To assess the stability of compound 1, the percentage of intact
1 relative to the combined amount of compound 1 and degradation
product 3 was determined at a given time point, in both the cell pel-
let and supernatant. To assess the cell uptake of compound 1, the
percentage of the combined amounts of intact compound 1 and deg-
radation product 3, relative to the total amount of compound 1
used (1 mM), was determined in the cell pellet at a given time point.
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